NLNK NewLink Genetics Corporation

1.64
-0.2  -11%
Previous Close 1.85
Open 1.9
Price To Book 0.5
Market Cap 61234477
Shares 37,224,606
Volume 828,548
Short Ratio
Av. Daily Volume 415,742

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 poster presentation at ASCO June 5, 2017.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase randomization portion will not be initiated - noted April 15, 2018.
Indoximod in combination with KEYTRUDA or Opdivo - Indigo301
Melanoma - cancer
Phase 2 data presented at ASCO 2018. Primary endpoint not met.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Phase 2 trial did not meet endpoints - noted June 2, 2017.
Indoximod + taxane
Cancer - breast
Phase 1b data to be presented at ASH December 2018.
Indoximod plus standard-of-care chemotherapy
Acute myeloid leukemia (AML)
Phase 1 updated data due 2019.
Indoximod in combination with chemotherapy and radiation
Diffuse intrinsic pontine glioma (DIPG)
Phase 1 initial data at SITC noted neither maximum tolerated dose (MTD), nor maximum biologically achievable dose (MBAD) has been reached.
NLG802
Solid tumors
Rolling BLA filing has commenced - noted November 13, 2018.
V920
Ebola